Kymera Therapeutics, Inc. Share Price & Technical Analysis
KYMR · $78.89 (-2.13%)
Healthcare / Biotechnology
$78.89
-2.13%
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRS…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-3% return in May, -8% avg return in past 3 year May month.
8% return in 2026, 53% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | 28% | -7% | -4% | -3% | – | – | – | – | – | – | – | 8% |
| 25 | -3% | -18% | -14% | 26% | -13% | 9% | -3% | -4% | 38% | 10% | 9% | 16% | 53% |
| 24 | 29% | 28% | -7% | -17% | -4% | -8% | 55% | 6% | -1% | -2% | -1% | -18% | 60% |
| 23 | 47% | -16% | -6% | 7% | -7% | -22% | -4% | -12% | -28% | -16% | 81% | 23% | 47% |
| 22 | -35% | -7% | 7% | -26% | -54% | 30% | 12% | 30% | -22% | 36% | -6% | -13% | -46% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.76B
P/E ratio
—
52W high
$103.0
52W low
$28.06
Volume
5,40,563
Beta
2.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Kymera Therapeutics, Inc. share price today?
- Kymera Therapeutics, Inc. (KYMR) last traded around $78.89 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KYMR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KYMR. Download the app for real-time alerts.
- How can I analyze Kymera Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.